Release Details

Cytori Reports Third Quarter 2016 Business and Financial Results

November 9, 2016

SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics (NASDAQ: CYTX) (“Cytori” or the “Company”) today announced its third quarter financial results and provided updates on its corporate activity and clinical development.

Third quarter 2016 net loss allocable to common stockholders was $5.4 million and $0.26 per share. Operating cash burn was approximately $4.6 million in the third quarter 2016. Cytori ended the third quarter of 2016 with approximately $15 million of cash and cash equivalents.

Selected Recent Highlights:

  • BARDA, a division of the U.S. Department of Health & Human Services, increased its contract funding to Cytori
  • Completed enrollment in its US STAR phase III trial for scleroderma hand dysfunction
  • Reported 48-week follow up data from US pilot/phase II ACT-OA trial
  • Additional limited regulatory approvals received by Cytori customers in Japan for use at their clinics of Cytori® Cell Therapy™ for osteoarthritis of the knee

Q3 and Year-to-date 2016 Financial Performance

  • Q3 2016 and year-to-date operating cash burn was $4.6 million and $15.4 million, compared to $6.2 million and $15.9 million for the same periods in 2015, respectively
  • Q3 2016 and year-to-date total revenues were $2.6 million and $8.4 million, compared to $2.5 million and $8.3 million for the same periods in 2015, respectively
  • Cash and debt principal balances at September 30, 2016 were approximately $15 million and $17.7 million, respectively
  • Q3 2016 net loss allocable to common stockholders was $5.4 million or $0.26 per share, compared to a net income of $1.5 million or $0.15 per share (or a net loss of $5.8 million and $0.56 per share when excluding a non-cash credit charge of $7.3 million related to the change in fair value of warrant liabilities) for the same period in 2015
  • Year-to-date net loss allocable to common stockholders was $17.1 million or $1.06 per share, compared to $16.6 million or $1.87 per share (or a net loss of $21 million or $2.36 per share, which excludes a non-cash charge of $5.0 million related to the change in fair value of warrant liabilities and a beneficial conversion feature charge for convertible preferred stock of $0.7 million) for the same period in 2015

“In Q3, we continued our focus on operational efficiency and maintaining momentum in our clinical development programs, we reduced our quarterly net losses by 7% and our operating cash burn by 25% from Q3’15 to Q3’16, respectively,” said Tiago Girao, VP of Finance and CFO of Cytori Therapeutics. “Our forecasts indicate that cash on hand coupled with efficient management of expenses, projected revenue growth, and modest influx of capital from a combination of business development activities and potential use of our ATM facility, will fund operations through mid 2017 and to important future milestones.”

Anticipated Forthcoming Milestones:

  • IDE approval for thermal burn trial related to our contract with BARDA
  • Report of 48-week US pivotal/phase III trial data for scleroderma hand dysfunction
  • Complete enrollment on Japanese phase III for urinary incontinence
  • Expansion of the Japanese osteoarthritis treatment centers

Updated 2016 Financial Guidance

The Company expects full year 2016 combined product and contract revenues to be lower than prior expectations based on the Company’s third quarter 2016 revenue results and the Company’s revised forecasts for the Managed Access Program fourth quarter 2016 product revenue.

  • Combined product and contract revenues anticipated to be within a range of $11 million to $13 million
  • Operating cash burn anticipated to be within a range of $19 million to $20 million

Management Conference Call Webcast

Cytori will host a management conference call at 5:30 p.m. Eastern Time today to further discuss the Company's progress. The webcast will be available live and by replay two hours after the call and may be accessed under "Webcasts" in the Investor Relations section of Cytori's website. If you are unable to access the webcast, you may dial in to the call at +1.877.402.3914, Conference ID: 9218454.

About Cytori

Cytori Therapeutics is a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. For more information: visit

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements that involve known and unknown risks and uncertainties. All statements, other than historical facts are forward looking statements. Such statements, including, without limitation, statements regarding having forecasted cash on hand sufficient to fund operations through 2017 (based upon expected expense containment, revenue growth and modest ATM usage), anticipated FDA approval of Cytori’s IDE submission for a thermal burn trial, anticipated receipt and disclosure of 48-week STAR data, completion of enrollment of the Cytori-supported, investigator-initiated Phase III ADRESU trial (male stress urinary incontinence), expected expansion in the number of clinic in Japan that apply for and receive regulatory approval to use Cytori Cell Therapy for knee osteoarthritis, and reiterated financial guidance (projected operating cash burn and total revenues for FY 2016) are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks include clinical, pre-clinical and regulatory uncertainties, such as those associated with conduct and completion of the Company-sponsored ACT-OA and STAR trials and proposed BARDA would trial, as well as the Company-supported, investigator-initiated SCLERADEC-II and ADRESU trials. Specifically, the Company faces risks relating to failure to achieve full enrollment of SCLERADEC II and ADRESU trials, risks in the collection and results of ACT-OA, STAR, SCLERADEC II, ADRESU and other clinical data and related final clinical outcomes (including the risk that clinical data from one or more of these clinical trials will fail to demonstrate safety or efficacy of the Cytori Cell Therapy, and risks that insufficiently positive clinical data will adversely affect the regulatory approval pathways and commercial prospects for ECCS-50, CCO-50, DCCT-10 and the Company’s other potential products. Some of these risks also include risks relating to regulatory challenges the Company faces (including the U.S., EU, China, Japan and its other key geographies) due to a number of factors including novelty of the Company’s technology and product offerings, changes in and /or evolution of regulatory approaches to cellular therapeutics like the Company’s in its key geographies, and similar matters. The Company also face risks relating to achievement of the Company’s financial goals (including 2016 operating cash burn and 2016 total revenues), dependence on third party performance and approvals (including performance of investigator-initiated trials, and outcome of FDA review of the Company’s proposed burn wound trial pursuant to its contract with BARDA), performance and acceptance of the Company’s products in clinical studies/trials and in the marketplace (including the Company’s ability to successfully implement and conduct its EU managed access program, commercial acceptance of the Company’s products in Japan and other markets where are products are commercially available, and similar risks), material changes in the marketplace that could adversely impact revenue projections (including changes in market perceptions of the Company’s products, and introduction of competitive products), unexpected costs and expenses that could adversely impact liquidity and shorten the Company’s current liquidity projections (which could in turn require the Company to seek additional debt or equity capital sooner than currently anticipated), the Company’s reliance on key personnel, the Company’s ability to identify and develop new programs or assets to expand the Company’s clinical pipeline, the right of the U.S. government (BARDA) to cut or terminate further support of the thermal burn injury program (including any decision by BARDA not to proceed with a wound trial in 2016, assuming FDA approval of the Company’s IDE submission), the Company’s abilities to capitalize on its internal restructuring and achieve break-even or profitability (or to continue to reduce our operating losses), and other risks and uncertainties described under the "Risk Factors" in Cytori's Securities and Exchange Commission Filings, included in the Company’s annual and quarterly reports.

There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. Federal securities laws to do so.


As of September 30,


As of December 31,

Current assets:                    
Cash and cash equivalents     $ 14,924,000       $ 14,338,000  
Accounts receivable, net of reserves of $173,000 and $797,000 in 2016 and 2015,


      918,000         1,052,000  
Inventories, net       3,946,000         4,298,000  
Other current assets       1,253,000         1,555,000  
Total current assets       21,041,000         21,243,000  
Property and equipment, net       1,292,000         1,631,000  
Restricted cash and cash equivalents       350,000         350,000  
Other assets       1,474,000         1,521,000  
Intangibles, net       8,763,000         9,031,000  
Goodwill       3,922,000         3,922,000  
Total assets     $ 36,842,000       $ 37,698,000  
Liabilities and Stockholders’ Equity                    
Current liabilities:                    
Accounts payable and accrued expenses     $ 5,637,000       $ 6,687,000  
Current portion of long-term obligations, net of discount       5,267,000          
Joint venture purchase obligation               1,750,000  
Total current liabilities       10,904,000         8,437,000  
Deferred revenues       97,000         105,000  
Long-term deferred rent and other       41,000         269,000  
Long-term obligations, net of discount, less current portion       12,130,000         16,681,000  
Total liabilities       23,172,000         25,492,000  
Commitments and contingencies                    
Stockholders’ equity:                    
Series A 3.6% convertible preferred stock, $0.001 par value; 5,000,000 shares

authorized; 13,500 shares issued; no shares outstanding in 2016 and 2015

Common stock, $0.001 par value; 75,000,000 shares authorized; 20,495,069 and

13,003,893 shares issued and outstanding in 2016 and 2015, respectively

      20,000         13,000  
Additional paid-in capital       387,119,000         368,214,000  
Accumulated other comprehensive income       675,000         996,000  
Accumulated deficit       (374,144,000 )       (357,017,000 )
Total stockholders’ equity       13,670,000         12,206,000  
Total liabilities and stockholders’ equity     $ 36,842,000       $ 37,698,000  

For the Three Months Ended
September 30,


For the Nine Months Ended
September 30,

    2016     2015     2016     2015  
Product revenues   $ 731,000     $ 766,000     $ 3,190,000     $ 3,281,000  
Cost of product revenues     618,000       502,000       1,770,000       2,395,000  
Gross profit     113,000       264,000       1,420,000       886,000  
Development revenues:                                
Government contracts and other     1,879,000       1,711,000       5,163,000       5,002,000  
      1,879,000       1,711,000       5,163,000       5,002,000  
Operating expenses:                                
Research and development     3,960,000       4,352,000       13,334,000       14,363,000  
Sales and marketing     818,000       566,000       2,742,000       2,059,000  
General and administrative     2,011,000       2,370,000       6,625,000       7,662,000  
Change in fair value of warrant liabilities           (7,310,000 )           (4,988,000 )
Total operating expenses     6,789,000       (22,000 )     22,701,000       19,096,000  
Operating (loss) income     (4,797,000 )     1,997,000       (16,118,000 )     (13,208,000 )
Other income (expense):                                
Income (loss) on asset disposal           (3,000 )     2,000       6,000  
Loss on debt extinguishment                       (260,000 )
Interest income     4,000       3,000       8,000       6,000  
Interest expense     (645,000 )     (669,000 )     (1,947,000 )     (2,677,000 )
Other income, net     54,000       199,000       928,000       152,000  
Total other expense     (587,000 )     (470,000 )     (1,009,000 )     (2,773,000 )
Net (loss) income   $ (5,384,000 )   $ 1,527,000     $ (17,127,000 )   $ (15,981,000 )
Beneficial conversion feature for convertible preferred stock                       (661,000 )
Net (loss) income allocable to common stockholders   $ (5,384,000 )   $ 1,527,000     $ (17,127,000 )   $ (16,642,000 )
Net income (loss) per share allocable to common stockholders                                
Basic   $ (0.26 )   $ 0.15     $ (1.06 )   $ (1.87 )
Diluted   $ (0.26 )   $ 0.15     $ (1.06 )   $ (1.87 )
Weighted average shares used in calculating net income (loss) per

share allocable to common stockholders

Basic     20,493,840       10,253,231       16,147,042       8,878,276  
Diluted     20,493,840       10,531,264       16,147,042       8,878,276  
Comprehensive (loss) income:                                
Net (loss) income   $ (5,384,000 )   $ 1,527,000     $ (17,127,000 )   $ (15,981,000 )
Other comprehensive (loss) income – foreign currency translation


    58,000       110,000       (321,000 )     361,000  
Comprehensive (loss) income   $ (5,326,000 )   $ 1,637,000     $ (17,448,000 )   $ (15,620,000 )
    For the Nine Months Ended

September 30,

    2016     2015  
Cash flows from operating activities:                
Net loss   $ (17,127,000 )   $ (15,981,000 )
Adjustments to reconcile net loss to net cash used in operating activities:                
Depreciation and amortization     794,000       761,000  
Amortization of deferred financing costs and debt discount     714,000       714,000  
Joint Venture acquisition obligation accretion     24,000       340,000  
Provision for expired inventory     26,000        
Change in fair value of warrants           (4,988,000 )
Stock-based compensation expense     925,000       1,617,000  
Loss on asset disposal     2,000       5,000  
Loss on debt extinguishment           260,000  
Increases (decreases) in cash caused by changes in operating assets and liabilities:                
Accounts receivable     91,000       131,000  
Inventories     190,000       (10,000 )
Other current assets     205,000       (258,000 )
Other assets     32,000       762,000  
Accounts payable and accrued expenses     (1,013,000 )     870,000  
Deferred revenues     (8,000 )     41,000  
Long-term deferred rent     (227,000 )     (210,000 )
Net cash used in operating activities     (15,372,000 )     (15,946,000 )
Cash flows from investing activities:                
Purchases of property and equipment     (110,000 )     (544,000 )
Expenditures for intellectual property           (13,000 )
Net cash used in investing activities     (110,000 )     (557,000 )
Cash flows from financing activities:                
Principal payments on long-term obligations           (25,032,000 )
Proceeds from long-term obligations           17,700,000  
Debt issuance costs and loan fees           (1,854,000 )
Joint Venture purchase payments     (1,774,000 )     (1,623,000 )
Proceeds from exercise of employee stock options and warrants           4,986,000  
Proceeds from sale of common stock, net     17,702,000       26,749,000  
Dividends paid on preferred stock           (75,000 )
Net cash provided by financing activities     15,928,000       20,851,000  
Effect of exchange rate changes on cash and cash equivalents     140,000        
Net increase in cash and cash equivalents     586,000       4,348,000  
Cash and cash equivalents at beginning of period     14,338,000       14,622,000  
Cash and cash equivalents at end of period   $ 14,924,000     $ 18,970,000  


Source: Cytori Therapeutics

Cytori Therapeutics

Tiago Girao